Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Quotient Clinical, a business unit of Quotient Bioresearch, has expanded its clinical facilities in Nottingham, UK, in response to customer adoption of its Synthesis-to-Clinic human ADME service.
Subscribe to our email newsletter
The expanded facility’s bed capacity has been increased by 50%.
The facility houses a sample processing laboratory for human ADME studies.
The UK regulatory authority – the Medicines and Healthcare products Regulatory Agency (MHRA), has inspected and approved the new facilities and awarded Supplementary Accreditation.
Synthesis-to-Clinic integrates each component required to undertake a 14C-enabled clinical study into a single supply chain, spanning 14C API radiosynthesis through to the clinical study report.
Quotient Clinical MD Mark Egerton said in parallel with the recent expansion of their Pharmaceutical Sciences laboratory and GMP drug product manufacturing facility, the completion of this clinical expansion is another milestone in the development of their business.
"Our expanded facilities will assist the continued development of our services, supporting our customers in taking new and innovative approaches in early drug development," Egerton said.